{"id":9688,"date":"2004-06-02T14:39:04","date_gmt":"2004-06-02T14:39:04","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=9688"},"modified":"2014-05-22T17:11:23","modified_gmt":"2014-05-22T17:11:23","slug":"tenofovir-blocks-viral-replication-in-hbv-monoinfected-and-in-hiv-hbv-coinfected-patients-with-lamivudine-resistance","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/9688","title":{"rendered":"Tenofovir blocks viral replication in HBV monoinfected and in HIV-HBV coinfected patients with lamivudine resistance"},"content":{"rendered":"<p><strong>HIVandHepeatitis.com<\/strong><\/p>\n<p><strong>Researchers evaluated the additional effect of tenofovir (Viread) on hepatitis B virus (HBV) viral dynamics after HBV DNA breakthrough during lamivudine (Epivir-HBV) therapy.<\/strong><\/p>\n<p>Eleven chronic HBV patients (five HIV coinfected) with breakthrough HBV DNA and the presence of a YMDD mutation received \u201cadd-on\u201d tenofovir 300 mg once daily, while maintaining their existing therapy, including lamivudine.<\/p>\n<p>Sequential sera, taken at day 1; t=0 and t=8 hours, day 2, 4, 7, 10, 14, 21, 28 and thereafter every 4 weeks, were tested for HBV DNA using PCR. Mean baseline log HBV DNA was 8.31 +\/- 1.07 (median 8.62; range 6.48-9.76 log HBV DNA).<\/p>\n<p>Application of tenofovir resulted in a mean log HBV DNA decline of 2.54 +\/- 0.91 after 4 weeks of tenofovir treatment and a mean decline of 4.95 +\/- 0.90 log HBV DNA after 24 weeks of treatment.<\/p>\n<p>The authors conclude: \u201cThese data show that tenofovir is capable of blocking viral replication in patients with lamivudine induced mutant viruses in HBV patients as well as in HBV\/HIV co-infected patients.\u201d<\/p>\n<p>Reference:<\/p>\n<p>de Man RA et al. Viral dynamics with frequent sampling during tenofovir therapy in patients with lamivudine-resistant hepatitis B virus mutants. Abstract 427. 39th EASL, 14-18 April 2004, Berlin, Germany.<\/p>\n<p>\u00a9 Copyright 2004 by HIV and Hepatitis.com. All Rights Reserved. Reproduction for personal or educational use is encouraged and does not require permission. Written permission is required to re-print copyrighted articles but is usually granted (email\u00a0<a href=\"mailto:publisher@HIVandHepatitis.com\">publisher@HIVandHepatitis.com<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIVandHepeatitis.com Researchers evaluated the additional effect of tenofovir (Viread) on hepatitis B virus (HBV) viral dynamics after HBV DNA breakthrough during lamivudine (Epivir-HBV) therapy. Eleven chronic HBV patients (five HIV coinfected) with breakthrough HBV DNA and the presence of a &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-9688","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=9688"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9688\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=9688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=9688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=9688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}